Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
NCT ID: NCT02598570
Last Updated: 2017-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
7 participants
INTERVENTIONAL
2015-11-30
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)
NCT02038933
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
NCT05658562
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT00568815
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
NCT00412997
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
NCT02038946
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
duvelisib
Duvelisib will be administered orally as a fixed dose in 28-day cycles.
duvelisib
Duvelisib will be administered orally as a fixed dose in 28-day cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
duvelisib
Duvelisib will be administered orally as a fixed dose in 28-day cycles.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Progressed during, refractory to, intolerant of, or ineligible for established therapy, or has a disease for which there is no established therapy
* Eastern Cooperative Oncology Group (ECOG) performance status lower than or equal to 2
* Life expectancy of at least 3 months
Exclusion Criteria
* Ongoing treatment with chronic immune-suppressants
* Overt CNS lymphoma
* Inadequate hepatic, bone marrow, or renal function
* History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
* Venous thromboembolic event requiring anticoagulation
* Presence of active systemic infection within 72 hours of treatment
* Human immunodeficiency virus (HIV) infection
* Pregnant or lactating women
20 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Infinity Pharmaceuticals, Inc.
INDUSTRY
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 141826
Aichi, , Japan
Site Reference ID/Investigator# 141595
Fukuoka, , Japan
Site Reference ID/Investigator# 141594
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M15-460
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.